7 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
EUROlinkCAT: Establishing a linked European Cohort of Children with Congenital Anomalies (EUROlinkCAT)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
Over 130,000 children born in Europe every year will have a congenital anomaly (CA; birth defect). These CAs, which are often rare diseases, are a major cause of infant mortality, childhood morbidity and long-term disability. EUROCAT is an established European network of population-based registries for the epidemiologic surveillance of CAs. EUROlinkCAT will use the EUROCAT infrastructure to suppor ...
Voir le projet
25
Participants partenaires
TERMINÉ
Antimicrobial FLEXible POLymers for its use in hospital environments (FLEXPOL)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2019,
FLEXPOL aims to develop a pilot line for the production of a cost effective antimicrobial (AM) adhesive film for its use in hospitals. The obtained adhesive film will inhibit growth of a wide range of microbes and will be suitable for high-touch surfaces, providing a durable protection with good resistance. It will assure the highest level of hygiene and patient safety, reducing the use of disinfe ...
Voir le projet
11
Participants partenaires
TERMINÉ
A New GEnetic LABoratory for non-invasive prenatal diagnosis (ANGELab)
Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,
This project will develop a family of In-Vitro Diagnostic Systems that will transfer for the first time novel Non Invasive Prenatal Diagnostic (NIPD) methods in tube to a LabonaChip format. This family will consist of three research systems chosen to cover all prenatal diagnosis models:- ANGELAB1. This system will use a LabonaChip to extract fetal DNA from the mother´s plasma based on differences ...
Voir le projet
16
Participants partenaires
TERMINÉ
Role of SOX9-BMI1 in adult neural stem cells and in glioma stem cells (SOX-BMI1)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2016,
"Cancers display remarkable phenotypical and functional intratumoral heterogeneity. The discovery of a rare subpopulation of tumor cells that acquired stem cells properties in several malignancies has profound implications for cancer therapy. These cells are suppose to be responsible for the origin, progression and recurrence of the tumors. Thus, new strategies directly targeting cancer stem cells ...
Voir le projet
1
Participant partenaire
TERMINÉ
EPIC-CVD: Individualised CVD risk assessment: tailoring targeted and cost-effective approaches to Europe's diverse populations (EPIC-CVD)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,
"EPIC-CVD's overarching goal is to provide clinicians and policy-makers with a menu of evidence-based options for cost-effective individualised risk assessment that enables the EU's increasingly resource-constrained economies to achieve more personalised predictive medicine in harmony with Europe's diverse cultures and healthcare systems.We will achieve this through developing and validating innov ...
Voir le projet
33
Participants partenaires
TERMINÉ
Red Transfronteriza de Investigación Biomédica de los Pirineos- Establecimiento de una Red de colaboración estable entre Centros de Investigación Biomédica en el espacio Pirineos (BIOMED-PIRINEOS)
Date du début: 31 mai 2012, Date de fin: 29 nov. 2014,
La cooperación en el ámbito de la investigación Biomédica es fundamental para la consecución de objetivos de gran envergadura e impacto debido a necesidad de inversiones elevadas en equipamiento, así como el alto nivel de especialización y la diversidad de perfiles de los recursos humanos implicados. BIOMED Pirineos está por tanto alineado con las prioridades regionales en materia de Salud, por lo ...
Voir le projet
8
Participants partenaires
TERMINÉ
Development of a strategy to treat limb-girdle muscular dystrophy (LGMD2A) using combined cell and gene therapy strategies (LGMD2A)
Date du début: 1 juil. 2010, Date de fin: 29 nov. 2014,
In Duchenne muscular dystrophy, several mutations can be corrected by the exon-skipping technique on cells. In limb-girdle muscular dystrophy type 2A (LGMD2A), however, all the mutations described to date do not seem to be good candidates for the RNA correction technology. The recently identified c.1782+1072 G>C mutation in LGMD2A patients could be potentially repaired at RNA level. The princip ...
Voir le projet